Literature DB >> 20691385

Current and emerging strategies for treating hepatic encephalopathy.

Keith J Foster1, Sonia Lin, Charles J Turck.   

Abstract

Hepatic encephalopathy (HE) is caused by liver impairment and has a multitude of symptoms in affected patients, including change in level of consciousness, intellectual function, and neuromuscular function. Pharmacologic therapy includes use of nonabsorbable disaccharides (lactulose and lactitol), and antibiotics such as neomycin, paromycin, metronidazole, and rifaximin. Probiotics, acarbose, and drugs such as L-carnitine and flumazenil, may also be helpful in treating HE. (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20691385     DOI: 10.1016/j.ccell.2010.04.007

Source DB:  PubMed          Journal:  Crit Care Nurs Clin North Am        ISSN: 0899-5885            Impact factor:   1.326


  9 in total

Review 1.  Probiotics in hepatology.

Authors:  Jan Lata; Jana Jurankova; Marcela Kopacova; Petr Vitek
Journal:  World J Gastroenterol       Date:  2011-06-28       Impact factor: 5.742

2.  Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders.

Authors:  Roland Posset; Angeles Garcia-Cazorla; Vassili Valayannopoulos; Elisa Leão Teles; Carlo Dionisi-Vici; Anaïs Brassier; Alberto B Burlina; Peter Burgard; Elisenda Cortès-Saladelafont; Dries Dobbelaere; Maria L Couce; Jolanta Sykut-Cegielska; Johannes Häberle; Allan M Lund; Anupam Chakrapani; Manuel Schiff; John H Walter; Jiri Zeman; Roshni Vara; Stefan Kölker
Journal:  J Inherit Metab Dis       Date:  2016-04-22       Impact factor: 4.982

3.  Lactulose decreases neuronal activation and attenuates motor behavioral deficits in hyperammonemic rats.

Authors:  Natália Ferreira Mendes; Flora França Nogueira Mariotti; José Simões de Andrade; Milena de Barros Viana; Isabel Cristina Céspedes; Márcia Regina Nagaoka; Luciana Le Sueur-Maluf
Journal:  Metab Brain Dis       Date:  2017-09-05       Impact factor: 3.584

Review 4.  Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.

Authors:  Giulia Malaguarnera; Maria Giordano; Giuseppe Nunnari; Gaetano Bertino; Michele Malaguarnera
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

Review 5.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

6.  RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.

Authors:  Christian Schulz; Kerstin Schütte; Siegfried Kropf; Friedhelm C Schmitt; Riccardo Vasapolli; Leon M Kliegis; Antonia Riegger; Peter Malfertheiner
Journal:  Trials       Date:  2016-02-29       Impact factor: 2.279

7.  Hepatic Encephalopathy in Patients in Lviv (Ukraine).

Authors:  Herbert Djiambou-Nganjeu
Journal:  J Transl Int Med       Date:  2018-10-09

8.  Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis.

Authors:  Christopher B Hergott; Aoife M Roche; Edwin Tamashiro; Thomas B Clarke; Aubrey G Bailey; Alice Laughlin; Frederic D Bushman; Jeffrey N Weiser
Journal:  Blood       Date:  2016-03-17       Impact factor: 22.113

9.  Microbial translocation in chronic liver diseases.

Authors:  Marilia Rita Pinzone; Benedetto Maurizio Celesia; Michele Di Rosa; Bruno Cacopardo; Giuseppe Nunnari
Journal:  Int J Microbiol       Date:  2012-07-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.